Full-Time

Senior/Executive Medical Director

Medical Affairs Strategy, Oncology

Posted on 6/26/2025

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilar biologics

Compensation Overview

$260k - $325k/yr

San Carlos, CA, USA

Hybrid

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • MD degree and 10+ years broad bio/pharmaceutical industry experience in a pharmaceutical/biotech setting
  • 5+ years of proven Medical Affairs leadership, building and implementing a successful Medical Affairs strategy and infrastructure
  • Strong analytical and problem-solving skills, with an ability to evaluate scientific data and medical literature and the ability to extrapolate to medical, marketing, or sales programs required
  • Understanding of the US Healthcare system, the pharmaceutical industry, and clinical and health economic practices in the US is required
  • Strong oral, written, and presentation skills with a thorough understanding of current medical oncology practice and the willingness to learn new areas of oncology
  • The successful candidate must thrive working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful and efficient in that setting. Must excel in a multidisciplinary environment as an integral leader and provide medical science leadership within assigned teams. Ability to analyze complex issues to develop relevant and realistic plans, programs and recommendations is essential.
  • Excellent and impactful written and verbal communication skills, strong problem-solving ability, and self-motivated. A hands-on approach to performing duties with a strong self-directed work ethic and attention to detail and quality are critical to success
  • Executive presence; confident, positive attitude, and enthusiastic.
  • Knowledge of multiple therapeutic areas related to Coherus immune-oncology portfolio, as well as proficient experience in oncology and immuno-oncology. Internal medicine and oncology experience/training is preferred.
  • Extensive and recent product launch experience in oncology, having successfully launched key products/brands preferred.
  • Broad working knowledge of FDA requirements, industry compliance.
  • Experience with US market medical promotional review preferred
Responsibilities
  • Lead the development and implement the Medical Affairs strategic plan across Coherus’ immuno-oncology portfolio (marketed and investigational products). Measure and assess the effectiveness of the US Medical plans regularly
  • Medical Affairs product lifecycle management (including real world evidence strategy) and launch readiness plans
  • Lead development and execution of competitive intelligence plan and deliverables
  • Develop Investigator Initiated Trials (IIT) strategy including areas of interest and budget. Oversee and serve as Chair and coordinator/administrator of the IIT program, consistently engage with HCPs to understand their evolving medical needs, identify knowledge gaps, and evolve IIT research areas of interest
  • Oversee the CME program and serve as the CME program coordinator
  • Provide medical expertise and approval of US promotional materials
  • Provide medical expertise and approval (if applicable) of non-promotional materials including but not limited to data analytics
  • Review and approve all standard and custom Medical Information response letters
  • Lead advisory boards in collaboration with Clinical Development to drive input for lifecycle management, HCP education etc.
  • Serve as member of the Product Development Team(s)
  • Cultivate relationships with diverse external audience including but not limited to medical and scientific experts, clinical researchers, academic institutions, community oncology, and research consortia, to assess unmet medical needs to develop and execute appropriate medical strategy
  • Serve as medical expert presenter and educator for internal and external needs (advisory boards, round tables, promotional speaker training, investigator meetings, congress presentation, etc.)
  • Contribute to medical communications by authorizing and/or reviewing abstracts, presentations and manuscripts for medical accuracy and content
  • Participate in medical and cross-functional strategy meetings and provide medical expertise including the safety review team
  • Assess, develop, and execute research collaborations across Coherus portfolio products
  • Oversee and execute Medical Affairs sponsored clinical studies including development and review of study protocols
  • Develop, refine and implement all required Medical Affairs policies, procedures and SOPs
  • Provide Medical expertise to the Commercial organization in a compliant manner as needed to assist in the development and execution of commercial activities
  • Provide medical expertise and input for new product licensing and acquisition opportunities and study protocols for clinical collaborations
  • Represent Coherus at key medical conferences and external events
  • Foster a culture of 100% compliance
Desired Qualifications
  • Knowledge of FDA requirements, industry compliance is mentioned as a desirable in some contexts but already in requirements; include as desirable as it appears: Broad working knowledge of FDA requirements, industry compliance.
  • Experience with US market medical promotional review preferred
  • Internal medicine and oncology experience/training is preferred
  • Extensive and recent product launch experience in oncology, having successfully launched key products/brands preferred
  • Executive presence is listed as desirable in job; include
  • Multiple therapeutic areas knowledge preferred

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • LOQTORZI revenue doubled to $40.8M in 2025, targeting $175M run-rate by 2028.
  • Debt slashed 90% from $480M to $38.8M, saving $15M annual interest.
  • $50M raised February 2026 funds LOQTORZI commercialization and pipeline.

What critics are saying

  • Commercial chief exit stalls LOQTORZI Q1 2026 sales ramp to $15M quarterly.
  • Apotex deal transfers Canadian toripalimab rights, eroding North American revenue.
  • Keytruda dominance caps LOQTORZI below $30M quarterly breakeven in 18 months.

What makes Coherus BioSciences unique

  • Pioneers next-generation PD-1 inhibitor LOQTORZI for nasopharyngeal carcinoma.
  • Advances Tagmokitug anti-CCR8 and casdozokitug IL-27 antibodies in oncology pipeline.
  • Transforms from biosimilars to innovative immuno-oncology combination therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 10th, 2026
Coherus Oncology doubles LOQTORZI revenue to $41M, slashes debt by 90% to $39M

Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.

Yahoo Finance
Mar 8th, 2026
Coherus cuts debt 90%, LOQTORZI sales double in 2025, eyes $175M annual run rate by 2028

Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.

MarketScreener
Feb 13th, 2026
Coherus Oncology prices $50M public offering at $1.75 per share to fund LOQTORZI commercialisation

Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.

Coherus Oncology
Jan 6th, 2026
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Coherus management to present at the 44th Annual J.P. Morgan Healthcare Conference. REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) - Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 13, 2026. About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

PharmiWeb.com
May 28th, 2025
Storm Therapeutics Announces First Patient Dosed In Clinical Collaboration To Evaluate Stc-15 In Combination With Loqtorzi® And Appointment Of Atif Abbas, M.D., As Chief Medical Officer

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor

INACTIVE